BCRX position history
The shares of Biocryst Pharmaceuticals (BCRX) that DAFNA Capital Management LLC reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2022 Q4: 251,000 shares, $2.9M, 0.81% of portfolio, New
- 2023 Q1: 551,500 shares, $4.6M, 1.4% of portfolio, Add +119.7%
- 2023 Q2: 569,000 shares, $4M, 1.1% of portfolio, Add +3.2%
- 2023 Q3: 652,000 shares, $4.6M, 1.4% of portfolio, Add +14.6%
- 2023 Q4: 709,500 shares, $4.2M, 1.0% of portfolio, Add +8.8%
- 2024 Q1: 709,500 shares, $3.6M, 0.82% of portfolio
- 2024 Q2: 704,500 shares, $4.4M, 1.0% of portfolio, Reduce −0.7%
- 2024 Q3: 667,000 shares, $5.1M, 1.2% of portfolio, Reduce −5.3%
- 2024 Q4: 667,000 shares, $5M, 1.3% of portfolio
- 2025 Q1: 558,255 shares, $4.2M, 1.2% of portfolio, Reduce −16.3%
- 2025 Q2: 218,255 shares, $2M, 0.54% of portfolio, Reduce −60.9%
- 2025 Q3: 218,255 shares, $1.7M, 0.41% of portfolio
- 2025 Q4: 418,255 shares, $3.3M, 0.76% of portfolio, Add +91.6%
- 2026 Q1: 430,248 shares, $4.1M, 0.93% of portfolio, Add +2.9%
- 2026 Q2: 400,248 shares, $4M, 0.76% of portfolio, Reduce −7.0%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|